Risk evaluation and mitigation strategies: Challenges and opportunities for health-system pharmacists

Stubbings, JoAnn; Joshi, Rutu A.; Hoffman, James M.
September 2010
American Journal of Health-System Pharmacy;9/15/2010, Vol. 67 Issue 18, p1547
Academic Journal
In this article the authors discuss the aspects of Risk Evaluation and Mitigation Strategy program (REMS) of the U.S. Food and Drug Administration (FDA). They present information on development, function and organizational structure of REMS. They also discuss the effect of REMS on pharmaceutical industry and pharmacists, and comment that REMS would provide opportunity for standardization of drug safety procedures.


Related Articles

  • AN ANALYSIS OF FDA'S DRUG SAFETY AUTHORITIES: CHALLENGES AND OPPORTUNITIES UNDER A NEW REGULATORY FRAMEWORK. Fain, Kevin M.; Nachman, Keeve E.; Rutkow, Lainie // New York University Journal of Legislation & Public Policy;Winter2014, Vol. 17 Issue 1, p1 

    The U.S. Food and Drug Administration (FDA) is responsible for ensuring the safety and effectiveness of all prescription drugs marketed in the United States. Beginning in the late 1990s, significant examples of risks emerged for FDA-approved drugs that had not been identified in studies...

  • OIG: Who Knows Whether REMS Improve Drug Safety? Serebrov, Mari // BioWorld Today;2/14/2013, Vol. 24 Issue 31, p1 

    The article offers the author's insights on the effectiveness of risk evaluation and mitigation strategies (REMS) in assuring drug safety. The author says that based on the Office of the Inspector General's (OIG's) report on February 13, 2013, there is no reliable method identified to assess the...

  • FDA tightens control over India’s API manufacturers. RAMESH, DEEPTI // Chemical Week;6/23/2014, Vol. 176 Issue 17, p31 

    The article examines regulation by the U.S. Food & Drug Administration (FDA) of active pharmaceutical ingredient (API) manufacturing plants located in India. Warning letters sent by the FDA to pharmaceutical industry firms including Apotex, Canton Laboratories and Fresenius following inspections...

  • The Case for Pediatric Exclusivity. Milne, Christopher // Pharmaceutical Technology;Sep2011, Vol. 35 Issue 9, p38 

    In this article the author comments the reauthorization of pediatric exclusivity provisions in the U.S. He notes that reauthorization of the pediatric exclusivity, which requested pharmaceutical industry to conduct pediatric studies in exchange of additional market protection under the Food and...

  • Back-to-Basics with PDUFA V. Radcliffe, Sara // Pharmaceutical Technology;Jun2012, Vol. 36 Issue 6, p12 

    The author reflects on the patient-centric approach to the Prescription Drug User Fee Act (PDUFA V) called by the Biotechnology Industry Organization (BIO). The author says that a set of PDUFA enhancement was agreed by the biotechnology, pharmaceutical industries, and the U.S. Food and Drug...

  • Growth of the Industry. Serebrov, Mari // BioWorld Today;7/18/2013, Vol. 24 Issue 136, p5 

    The article discusses the formation of the drug compounding industry. The U.S. Food and Drug Administration Modernization Act of 1997 exempts compounders from the premarket approval requirement for new drugs, mandatory good manufacturing compliance, and some directions for use requirements....

  • Feds to pharma: Fraud cases are in our crosshairs. KALTWASSER, JARED // njbiz;11/8/2010, Vol. 23 Issue 45, p5 

    The article considers the measures taken by pharmaceutical companies in the U.S. to comply with the regulations enforced by the Food and Drug Administration (FDA). According to Jack Garvey, principal at Compliance Architects, the pharmaceutical industry has changed from being vertically...

  • Policy Watch. Drug shortages challenge the healthcare community, FDA, and pharmaceutical manufacturers. Wechsler, Jill // Formulary;Nov2011, Vol. 46 Issue 11, p503 

    The article reports on increased attention which the U.S. health care system, the White House and the U.S. Congress is giving in 2011 to the problem of drug shortages involving drugs that are used to treat cancer, pain and other serious medical conditions. A discussion of problems which the...

  • Bigger Role. Bigger Target. Agres, Ted // Drug Discovery & Development;May2012, Vol. 15 Issue 5, p8 

    The article discusses the bigger role of the Food and Drug Administration (FDA) in the reauthorization of the Prescription Drug User Fee Act (PDUFA) in the U.S. It notes the five major provisions to be considered in the final bill in which FDA's new responsibilities and authorities for oversight...

  • FDA agrees to deal that speeds reviews. Arnold, Matthew // McKnight's Long-Term Care News;Oct2011, Vol. 32 Issue 10, p31 

    The article reports on the agreement between the U.S. Food and Drug Administration and the biopharmaceutical industry that the Prescription Drug User Fee Act, which requires drug firms to provide about two-thirds of the amount spent by the agency on drug reviews, should be revamped.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics